Podocyte protection by darbepoetin: preservation of the cytoskeleton and nephrin expression. (Q53557373)

15 May 2018

title

Podocyte protection by darbepoetin: preservation of the cytoskeleton and nephrin expression. (English)

1 reference

15 May 2018

0 references

0 references

N Eto

1

1 reference

15 May 2018

T Wada

2

1 reference

15 May 2018

R Inagi

3

1 reference

15 May 2018

H Takano

4

1 reference

15 May 2018

A Shimizu

5

1 reference

15 May 2018

H Kato

6

1 reference

15 May 2018

H Kurihara

7

1 reference

15 May 2018

H Kawachi

8

1 reference

15 May 2018

S J Shankland

9

1 reference

15 May 2018

T Fujita

10

1 reference

15 May 2018

M Nangaku

11

1 reference

15 May 2018

language of work or name

English

0 references

publication date

25 April 2007

1 reference

15 May 2018

published in

Kidney International

1 reference

15 May 2018

volume

72

1 reference

15 May 2018

issue

4

1 reference

15 May 2018

page(s)

455-463

1 reference

15 May 2018

The podocyte's response to injury: role in proteinuria and glomerulosclerosis

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002311

7 January 2021

Podocyte biology and response to injury

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002311

7 January 2021

An ultrastructural study of the mechanisms of proteinuria in aminonucleoside nephrosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002311

7 January 2021

Modulation of cytoskeletal organization of podocytes during the course of aminonucleoside nephrosis in rats

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002311

7 January 2021

Nephrin expression is reduced in human diabetic nephropathy: evidence for a distinct role for glycated albumin and angiotensin II.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002311

7 January 2021

Proteinuria and the expression of the podocyte slit diaphragm protein, nephrin, in diabetic nephropathy: effects of angiotensin converting enzyme inhibition

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002311

7 January 2021

Altered ultrastructural distribution of nephrin in minimal change nephrotic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002311

7 January 2021

Pathogenesis of renal anemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002311

7 January 2021

EPO: renoprotection beyond anemia correction

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002311

7 January 2021

New avenues of exploration for erythropoietin

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002311

7 January 2021

Erythropoietin in experimental acute renal failure

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002311

7 January 2021

Pleiotropic renal actions of erythropoietin

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002311

7 January 2021

Low-dose therapy with the long-acting erythropoietin analogue darbepoetin alpha persistently activates endothelial Akt and attenuates progressive organ failure

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002311

7 January 2021

Endothelial progenitor cell proliferation and differentiation is regulated by erythropoietin Rapid Communication

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002311

7 January 2021

Induction of B7-1 in podocytes is associated with nephrotic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002311

7 January 2021

Induction of antioxidant enzymes in murine podocytes precedes injury by puromycin aminonucleoside

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002311

7 January 2021

Hsp27 regulates podocyte cytoskeletal changes in an in vitro model of podocyte process retraction

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002311

7 January 2021

Positionally cloned gene for a novel glomerular protein--nephrin--is mutated in congenital nephrotic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002311

7 January 2021

Co-localization of nephrin, podocin, and the actin cytoskeleton: evidence for a role in podocyte foot process formation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002311

7 January 2021

Cloning of rat nephrin: expression in developing glomeruli and in proteinuric states

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002311

7 January 2021

Cloning of rat homologue of podocin: expression in proteinuric states and in developing glomeruli

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002311

7 January 2021

Fluvastatin ameliorates podocyte injury in proteinuric rats via modulation of excessive Rho signaling

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002311

7 January 2021

Glucocorticoids protect and enhance recovery of cultured murine podocytes via actin filament stabilization

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002311

7 January 2021

Role of p38 mitogen-activated protein kinase activation in podocyte injury and proteinuria in experimental nephrotic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002311

7 January 2021

Glomerular localization of erythropoietin receptor mRNA and protein in neonatal and mature mouse kidney

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002311

7 January 2021

Erythropoietin receptor-mediated inhibition of exocytotic glutamate release confers neuroprotection during chemical ischemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002311

7 January 2021

Targeting of the Akt/PKB kinase to the actin skeleton.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002311

7 January 2021

Proteomics exploration reveals that actin is a signaling target of the kinase Akt.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002311

7 January 2021

PI3K induced actin filament remodeling through Akt and p70S6K1: implication of essential role in cell migration

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002311

7 January 2021

In vivo evidence that erythropoietin protects neurons from ischemic damage

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002311

7 January 2021

Erythropoietin protects the kidney against the injury and dysfunction caused by ischemia-reperfusion.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002311

7 January 2021

Derivatives of erythropoietin that are tissue protective but not erythropoietic

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002311

7 January 2021

A nonerythropoietic derivative of erythropoietin protects the myocardium from ischemia-reperfusion injury

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002311

7 January 2021

The impact of early normalization of haematocrit by erythropoietin on renal damage in the remnant kidney model

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002311

7 January 2021

Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002311

7 January 2021

The effect of correction of anaemia in diabetics and non-diabetics with severe resistant congestive heart failure and chronic renal failure by subcutaneous erythropoietin and intravenous iron

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002311

7 January 2021

r.hu-erythropoietin (EPO) treatment of pre-ESRD patients slows the rate of progression of renal decline

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002311

7 January 2021

Erythropoiesis-stimulating protein therapy and the decline of renal function: a retrospective analysis of patients with chronic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002311

7 January 2021

Treating anemia early in renal failure patients slows the decline of renal function: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002311

7 January 2021

Chronic hypoxia and tubulointerstitial injury: a final common pathway to end-stage renal failure

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002311

7 January 2021

Darbepoetin alfa administration to achieve and maintain target hemoglobin levels for 1 year in patients with chronic kidney disease.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002311

7 January 2021

Neuroprotective effect of darbepoetin alfa, a novel recombinant erythropoietic protein, in focal cerebral ischemia in rats

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002311

7 January 2021

A Single Bolus of a Long-acting Erythropoietin Analogue Darbepoetin Alfa in Patients with Acute Myocardial Infarction: A Randomized Feasibility and Safety Study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002311

7 January 2021

Phenotypic modulation of parietal epithelial cells of Bowman's capsule in culture

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002311

7 January 2021

Identifiers

DOI

10.1038/SJ.KI.5002311

1 reference

15 May 2018

Dimensions Publication ID

1008016731

0 references

1 reference

15 May 2018